Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Major adverse CV events were predicted in patients with recent ACS based on their lipoprotein(a) ...

Elevated concentrations of lipoprotein(a) are not associated with adverse cardiovascular outcomes among patients with a recent acute coronary syndrome treated with statins, according to a new ...

Marking World Heart Day (September 29), Arnab Roy, Kshama Pimpalgaonkar, Abhik Banerjee, and Faisal Khan, Division of R&D and Department of Biochemistry; (SRL Mumbai) elaborate on the Indian phenotype ...

Results showed that IRs of MACE and MI per 100 person-years increased corresponding with the patient’s 10-year ASCVD risk score. 2,3 However, a substantially significant increase was seen among those ...

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a new ...

Please provide your email address to receive an email when new articles are posted on . The risk for major adverse CV events after recent ACS could be predicted by baseline lipoprotein(a) and ...

CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for ...

Many more people are at risk for early cardiovascular events because of raised Lp(a) levels than from having familial hypercholesterolemia (FH), a new study suggests. The Danish study set out to try ...